Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Villejuif – page 44

929 clinical trials in Villejuif, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Villejuif at a glance
929
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

929 trials in Villejuif

Open in trial search

Neoplasm+1

Not recruiting

Study on Niraparib and Dostarlimab for Patients with DNA Repair-Deficient or Platinum-Sensitive Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Dostarlimab
  • Sponsor:Institut Gustave Roussy

Chronic graft versus host disease

Not recruiting

Study Comparing Axatilimab to Best Available Therapy for Patients with Chronic Graft-Versus-Host Disease After Two or More Treatments

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Axatilimab
  • Sponsor:Incyte Corp.

Adenocarcinoma gastric

Not recruiting

Study on the Effectiveness of Bemarituzumab and FLOT Chemotherapy for Patients with Resectable Gastric and Gastroesophageal Junction Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab
  • Sponsor:Institut De Cancerologie De L Ouest

Hepatitis D+1

Not recruiting

Study on Tobevibart and Elebsiran for Patients with Chronic Hepatitis D Virus Infection Not Responding to Bulevirtide Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bulevirtide
  • Sponsor:Vir Biotechnology Inc.

Non-small cell lung cancer metastatic

Not recruiting

Study of M9140 for Patients with Advanced Non-Small Cell Lung Cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Merck Healthcare KGaA

Metastatic gastric cancer

Not recruiting

Study of M9140 for Patients with Advanced Stomach Cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Merck Healthcare KGaA

Hormone-refractory prostate cancer

Not recruiting

Study Comparing BMS-986365 with Other Treatments for Patients with Metastatic Castration-resistant Prostate Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Celgene Corp.

Neoplasm malignant

Not recruiting

Study of PRT3789 and Pembrolizumab for Patients with Advanced Solid Tumors, Esophageal Cancer, or NSCLC with SMARCA4 Mutation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Prelude Therapeutics Inc.

Plasma cell myeloma

Not recruiting

Study Comparing Belantamab Mafodotin with Lenalidomide and Dexamethasone to Daratumumab with Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin
  • Sponsor:Glaxosmithkline Research & Development Limited

Neoplasm

Not recruiting

Study on the Safety and Effects of IPN01195 in Adults with Advanced Solid Tumors

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:IPN01195
  • Sponsor:Ipsen Pharma

Breast cancer+1

Not recruiting

Study of PF-07220060 and Letrozole for Adults with HR-Positive, HER2-Negative Advanced Breast Cancer Without Prior Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Pfizer Inc.

Endometrial cancer+4

Not recruiting

Study on Raludotatug Deruxtecan for Patients with Advanced or Metastatic Solid Tumors, Including Gynecological and Genitourinary Cancers

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Raludotatug Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Villejuif

What the registry says about research in the country

01 Oncology - Head and Neck Cancer

Innovative research focusing on locally advanced head and neck squamous cell carcinoma treatments, including novel therapies combined with radiotherapy and immunotherapy approaches.

  • NBTXR3 with radiotherapy
  • EGFR-ADC therapy combinations
  • HPV-positive oropharyngeal cancer
02 Gastrointestinal Oncology

Studies targeting various digestive system cancers, with particular focus on pancreatic adenocarcinoma and advanced gastric cancer treatments.

  • Anti-CEACAM5 ADC therapy
  • Sotorasib combinations
  • Novel gastrointestinal cancer treatments
03 Hematologic Malignancies

Cutting-edge research in multiple myeloma treatment, exploring new combination therapies and maintenance approaches.

  • Elranatamab-lenalidomide therapy
  • Belantamab mafodotin combinations
  • T-cell lymphoma treatments
04 Lung Cancer Research

Comprehensive studies in both non-small cell lung cancer and small cell lung cancer, investigating targeted therapies and immunotherapy combinations.

  • Novel antibody-drug conjugates
  • Microbiome-based approaches
  • Targeted therapy combinations
05 Advanced Solid Tumors

Broad-spectrum research investigating novel treatments for metastatic solid tumors, including innovative therapeutic approaches and combination strategies.

  • PARG inhibitor studies
  • Targeted molecular therapies
  • Immunotherapy combinations
Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.